Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
|Articles|June 20, 2005
Drugs in the winners' circle
Drugs in the winners' circle
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Drug Topics
1
GLP-1 Therapy Must Prioritize Metabolic Quality Over Weight Loss
2
FDA Approves Update for Winrevair Based on Phase 3 HYPERION Trial Data
3
PPV23 Vaccination Found to Not Reduce Cardiovascular Risk
4
COVID-19 Vaccine Hesitancy in 2026: How Attitudes Have Shifted
5